AAAAAA

   
Results: 1-13 |
Results: 13
Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval (vol 52, pg 201, 2001)
Authors: Gillen, MS Miller, B Chaikin, P Morganroth, J
Citation: Ms. Gillen et al., Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval (vol 52, pg 201, 2001), BR J CL PH, 52(3), 2001, pp. 343-343
Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval
Authors: Gillen, MS Miller, B Chaikin, P Morganroth, J
Citation: Ms. Gillen et al., Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval, BR J CL PH, 52(2), 2001, pp. 201-204
In vitro and in vivo techniques used in drug development for evaluation ofdose delivery of inhaled corticosteroids
Authors: Rhodes, GR Rohatagi, S Gillen, MS Deluccia, F Banerji, DD Chaikin, P
Citation: Gr. Rhodes et al., In vitro and in vivo techniques used in drug development for evaluation ofdose delivery of inhaled corticosteroids, J CLIN PHAR, 41(1), 2001, pp. 7-18
Measurement of the elasticity of the actin tail of Listeria monocytogenes
Authors: Gerbal, F Laurent, V Ott, A Carlier, MF Chaikin, P Prost, J
Citation: F. Gerbal et al., Measurement of the elasticity of the actin tail of Listeria monocytogenes, EUR BIOPHYS, 29(2), 2000, pp. 134-140
Pharmacokinetic/pharmacodynamic modeling in drug research and development
Authors: Derendorf, H Lesko, LJ Chaikin, P Colburn, WA Lee, P Miller, R Powell, R Rhodes, G Stanski, D Venitz, J
Citation: H. Derendorf et al., Pharmacokinetic/pharmacodynamic modeling in drug research and development, J CLIN PHAR, 40(12), 2000, pp. 1399-1418
Pharmacokinetics/pharmacodynamics in drug development: An industrial perspective
Authors: Chaikin, P Rhodes, GR Bruno, R Rohatagi, S Natarajan, C
Citation: P. Chaikin et al., Pharmacokinetics/pharmacodynamics in drug development: An industrial perspective, J CLIN PHAR, 40(12), 2000, pp. 1428-1438
Defining the maximum tolerated dose: An update
Authors: Cutler, NR Sramek, JJ Greenblatt, DJ Chaikin, P Collins, J
Citation: Nr. Cutler et al., Defining the maximum tolerated dose: An update, J CLIN PHAR, 40(11), 2000, pp. 1183-1183
Industry perspectives on the MTD: Growing acceptance in clinical development programs
Authors: Chaikin, P
Citation: P. Chaikin, Industry perspectives on the MTD: Growing acceptance in clinical development programs, J CLIN PHAR, 40(11), 2000, pp. 1191-1198
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization
Authors: Veyrat-Follet, C Bruno, R Olivares, R Rhodes, GR Chaikin, P
Citation: C. Veyrat-follet et al., Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization, CLIN PHARM, 68(6), 2000, pp. 677-687
An elastic analysis of Listeria monocytogenes propulsion
Authors: Gerbal, F Chaikin, P Rabin, Y Prost, J
Citation: F. Gerbal et al., An elastic analysis of Listeria monocytogenes propulsion, BIOPHYS J, 79(5), 2000, pp. 2259-2275
A review of the cardiac systemic side-effects of antihistamines: ebastine
Authors: Moss, AJ Chaikin, P Garcia, JD Gillen, M Roberts, DJ Morganroth, J
Citation: Aj. Moss et al., A review of the cardiac systemic side-effects of antihistamines: ebastine, CLIN EXP AL, 29, 1999, pp. 200-205
On the 'Listeria' propulsion mechanism
Authors: Gerbal, F Noireaux, V Sykes, C Julicher, F Chaikin, P Ott, A Prost, J Golsteyn, RM Friederich, E Louvard, D Laurent, V Carlier, MF
Citation: F. Gerbal et al., On the 'Listeria' propulsion mechanism, PRAMANA-J P, 53(1), 1999, pp. 155-170
Absolute oral versus inhaled bioavailability: Significance for inhaled drugs with special reference to inhaled glucocorticoids
Authors: Rohatagi, S Rhodes, GR Chaikin, P
Citation: S. Rohatagi et al., Absolute oral versus inhaled bioavailability: Significance for inhaled drugs with special reference to inhaled glucocorticoids, J CLIN PHAR, 39(7), 1999, pp. 661-663
Risultati: 1-13 |